secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001493152-25-001112
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 restores lifespan to near-normal in preclinical progeria model
------------------------------------------------------------------------

- In C. elegans with wrn-1 mutation (Werner Syndrome model), Telomir-1 restored lifespan to near-normal levels.
- Progeria causes rapid aging in children; these results suggest potential for Telomir-1 to address cellular aging issues.
- Telomir Pharmaceuticals (Nasdaq: TELO) announced the findings in an SEC filing on Jan 7, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225001112/0001493152-25-001112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225001112/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-001112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer